bezafibrate + diflunisal

Bezafibrate + diflunisal is an investigational fixed-dose combination of two small molecule drugs: bezafibrate, a fibrate-class lipid-lowering agent, and diflunisal, a nonsteroidal anti-inflammatory drug (NSAID). The combination was developed under the code name CRx-401 as a novel insulin sensitizer for the treatment of type 2 diabetes. Bezafibrate acts primarily as an agonist of peroxisome proliferator-activated receptor alpha (PPAR-alpha), reducing cholesterol and triglyceride levels while increasing HDL cholesterol. Diflunisal inhibits prostaglandin synthesis by blocking cyclooxygenase enzymes (prostaglandin G/H synthase 1 and 2), providing analgesic and anti-inflammatory effects. In this combination, low-dose diflunisal is used to synergistically enhance the anti-diabetic effects of bezafibrate through disease-targeted mechanisms that improve glycemic control without promoting weight gain. The product was developed by Zalicus (formerly CombinatoRx) for type 2 diabetes but does not appear to have reached regulatory approval[3][4][5].

Other names

bezafibrate + diflunisalCRx 401CRx401CRx-401